Compartmental inhibition of hepatic glutathione reductase activities by 1,3-bis(2-chloroethyl)-N-nitrosourea (BCNU) in Sprague-Dawley and Fischer-344 rats.
Administration of 1,3-bis(2-chloroethyl)-N-nitrosourea (BCNU) inhibits hepatic activities of glutathione reductase (GR) comparably in both adult male Fischer-344 (F344) and Sprague-Dawley (SD) rats in vivo. BCNU pretreatment greatly exacerbates the hepatic necrosis caused by diquat in F344 rats, but does not similarly potentiate liver injury in SD rats. The primary purpose of the present studies was to test the hypothesis that BCNU pretreatment would exhibit differences between the two strains in inhibition of GR activities in hepatic subcellular compartments that would correlate with the differing effects on diquat-induced hepatic necrosis. In the present studies, 16 h after administration of 80 mg/kg of BCNU, GR activities in the hepatic homogenates were 20-30% of activities in vehicle-treated controls. Neither the extents of inhibition nor the GR activities in hepatic cytosol, microsomes. mitochondria, or purified nuclei isolated by differential centrifugation were different between SD and F344 rats treated with BCNU. The results indicate that differences between SD and F344 rats in the effects of BCNU on susceptibilities to diquat-induced hepatic necrosis are not readily attributable to compartmentally selective inhibition of GR. In addition, hepatic O6-alkylguanine-DNA alkyltransferase (AGT, MGMT) levels were almost completely depleted in BCNU-treated rats of both strains, thus indicating that MGMT-dependent pathways are unlikely to be critical determinants of the effects of BCNU on this model of acute cell death mediated by reactive oxygen species in vivo.
Jopperi-Davis
Katrina S
KS
Section of Neonatology, Department of Pediatrics, Center for Developmental Pharmacology and Toxicology, Columbus Children's Research Institute, 700 Children's Drive, Rm. W202, Columbus, OH 43205, USA.
Park
Min Soo
MS
Rogers
Lynette K
LK
Backes
Carl H
CH
Lim
In Kyoung
IK
Smith
Charles V
CV
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000633:toxicity*; D002330:Carmustine / Q000008:administration & dosage / Q000633:toxicity*; D002451:Cell Compartmentation / Q000187:drug effects*; D002458:Cell Fractionation; D004791:Enzyme Inhibitors / Q000633:toxicity*; D005980:Glutathione Reductase / Q000037:antagonists & inhibitors*; D007274:Injections, Intraperitoneal; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D013045:Species Specificity
D018906:Antineoplastic Agents, Alkylating; D004791:Enzyme Inhibitors; D005980:Glutathione Reductase; D019853:O(6)-Methylguanine-DNA Methyltransferase; D002330:Carmustine